Obstructive sleep apnea: the new cardiovascular disease. Part I: obstructive sleep apnea and the pathogenesis of vascular disease

Khayat, Rami; Patt, Brian; Hayes, Don

doi:10.1007/s10741-008-9112-z

Cited by 65 publications

(51 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…P > .05 Kruskal Wallis, P < .05. b According to the age parameter there was a significant relationship between with and without CVD in the AHI !30 patients. atherosclerosis, and other cardiovascular outcomes via increasing the inflammation 52,[59][60][61]. Many studies have shown that increased RDW values are also related to adverse outcomes in cardiovascular as well as non-CVDs including peripheral artery disease, unstable angina, HT, heart failure, acute dyspnea, cardiovascular, and thrombotic disorders.…”

mentioning

confidence: 99%

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

et al. 2015

View full text Add to dashboard Cite

We investigated the role of the red cell distribution width (RDW) and other parameters including platelet (PLT) count, mean platelet volume (MPV), and platelet distribution width (PDW) in patients with obstructive sleep apnea syndrome (OSAS) having cardiovascular diseases (CVDs). Patients (n = 142) having sleep disorders and who applied for a night polysomnography were included in this study. For statistical analysis, chi-square test, bivarite correlation, and logistic and stepwise regression tests were used. A positive correlation between RDW MPV, RDW, and body mass index as well as PLT and apnea-hypopnea index were observed. A negative correlation between AHI and PDW (P= .041) and a positive correlation between AHI and PLT (P= .010) were found in the patients ≥40 years old with CVD. The RDW was higher in patients ≥40 years old who had CVD (P= .016), and 19% of them had RDW >14%. The PDW (odds ratio = 6.02 [95% confidence interval = 1.3-28.2],P= .023) appeared to be associated with increased risk of hyperlipidemia in patients with severe OSAS. If these results are confirmed, RDW could be used with other markers, especially PLT and PDW, in prediction of CVD in patients with severe OSAS.

show abstract

mentioning

confidence: 99%

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…With reperfusion, these reactions proceed with a sudden increase in ROS, which overwhelms usual cellular antioxidant defenses, leading to uncontrolled oxidation of vital cellular biomolecules (56). Experimental data support this hypothesis, and an expanding body of research suggests that it may apply to patients with sleep apnea as well (56,61–63). …”

Section: Pathophysiologic Consequencesmentioning

confidence: 84%

Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure

Costanzo

Khayat

Ponikowski

et al. 2015

Journal of the American College of Cardiology

Self Cite

123

View full text Add to dashboard Cite

Central sleep apnea (CSA) is a highly prevalent, though often unrecognized, comorbidity in patients with heart failure (HF). Data from HF population studies suggest that it may present in 30% to 50% of HF patients. CSA is recognized as an important contributor to the progression of HF and to HF-related morbidity and mortality. Over the past 2 decades, an expanding body of research has begun to shed light on the pathophysiologic mechanisms of CSA. Armed with this growing knowledge base, the sleep, respiratory, and cardiovascular research communities have been working to identify ways to treat CSA in HF with the ultimate goal of improving patient quality of life and clinical outcomes. In this paper, we examine the current state of knowledge about the mechanisms of CSA in HF and review emerging therapies for this disorder.

show abstract

“…Most recent studies in animal models of CIH as well as in OSA patients confirm that OSA is associated with oxidative stress, which generally correlates with the severity of sleep apnea. 16,23 CIH-provoked mild and transient oxidative stress can induce adaptation, but severe and persistent CIH may provoke maladaptation as in OSA patients if untreated. As oxidative imbalance has been accepted as a trigger for cardiac dysfunction, the early detection of increased oxidative stress in OSA patients is of importance for risk stratification and strict control regarding CPAP compliance and treatment.…”

Section: Discussionmentioning

confidence: 99%

8-isorpostanes – markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction

Cherneva¹,

Georgiev²,

Петрова³

et al. 2013

RRCC

View full text Add to dashboard Cite

Objective: Increased oxidative stress is considered to be an independent risk factor for cardiovascular diseases, but remains disputed in obstructive sleep apnea (OSA). Among oxidative stress markers, isorpostanes are considered to be the most sensitive and specific. Aims: The aim of the study was to compare urinary isorpostanes in patients with OSA and systolic dysfunction to patients with OSA and preserved ejection fraction (EF) and determine their role as markers for increased oxidative stress and early cardiac damage. Materials and methods: Urinary 8F2-isorpostanes were measured in 30 patients with OSA and mild systolic dysfunction (EF = 45.7% ± 6.17%) and compared to 15 patients with OSA and normal EF (EF = 60.3% ± 6.3%). Univariate regression analysis was performed to find predictors of left systolic dysfunction. Correlations between 8-isorpostanes, anthropometric, metabolic, and sleep study characteristics were explored. In addition, in 19 patients the effect of bilevel positive airway pressure (BiPAP) therapy was evaluated during a 3 month follow-up. Markers of hemodynamic stress, N-terminal prohormone of brain natriuretic peptide and oxidative stress, measured by 8-isorpostanes were compared before and after the follow-up. Results: Urinary levels of 8-isorpostanes were significantly higher in the group with mild systolic dysfunction in comparison to the controls with preserved EF (0.149 versus 0.049 pg/µL, P = 0.023). The regression analysis did not define them as predictors for left systolic dysfunction. Their urinary concentration correlated best to the average desaturation index (P = 0.043). Urinary 8-isorpostanes decreased as a result of BiPAP therapy after three months of follow-up (0.164 versus 0.098 pg/µL, P = 0.011). Conclusion: Urinary isorpostanes are reliable markers for chronic intermittent hypoxia and oxidative stress in OSA patients. They may be of clinical application for the early detection of patients at risk for cardiovascular damage and could help in the monitoring of the restoration of oxidative balance.

show abstract

Obstructive sleep apnea: the new cardiovascular disease. Part I: obstructive sleep apnea and the pathogenesis of vascular disease

Cited by 65 publications

References 145 publications

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure

8-isorpostanes – markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction

Contact Info

Product

Resources

About

Obstructive sleep apnea: the new cardiovascular disease. Part I: obstructive sleep apnea and the pathogenesis of vascular disease

Cited by 65 publications

References 145 publications

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

Hematological Parameters as Predictors of Cardiovascular Disease in Obstructive Sleep Apnea Syndrome Patients

Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure

8-isorpostanes &ndash; markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction

Contact Info

Product

Resources

About

8-isorpostanes – markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction